Epigenetic changes may contribute to the pathogenesis of cholesteatoma through dysregulation of several biological pathways. Further studies identifying specific targets such as miRNA-21 and those investigating DNA methylation and histone modifications have the potential to develop biomarkers and targeted pharmaceutical agents for the treatment of cholesteatoma.
Brar et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: